Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 USD | -0.67% | +18.70% | +43.18% |
Apr. 29 | LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors | CI |
Apr. 23 | BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 6.082 | 137.1 | 118.4 | 61.01 | 325 | 482.4 | - |
Enterprise Value (EV) 1 | 6.082 | 137.1 | 77.74 | 61.01 | 325 | 482.4 | 482.4 |
P/E ratio | -1.64 x | -1.47 x | -1.69 x | -1.24 x | -11.8 x | -27.6 x | -54.3 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 2.4 x | 1.97 x |
EV / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 2.4 x | 1.97 x |
EV / EBITDA | - | -8.43 x | -3.09 x | -4.16 x | 27.1 x | 24.8 x | 17.9 x |
EV / FCF | - | -11.3 x | -3.25 x | - | - | 107 x | 32.4 x |
FCF Yield | - | -8.85% | -30.8% | - | - | 0.94% | 3.09% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,578 | 20,992 | 30,593 | 31,450 | 39,203 | 40,366 | - |
Reference price 2 | 0.5750 | 6.530 | 3.870 | 1.940 | 8.290 | 11.95 | 11.95 |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 37.29 | 92.88 | 119 | 152.5 | 201.3 | 245 |
EBITDA 1 | - | -16.26 | -38.28 | -14.66 | 11.98 | 19.45 | 26.9 |
EBIT 1 | - | -57.82 | -54.3 | -43.45 | -14.49 | -2.136 | -0.363 |
Operating Margin | - | -155.04% | -58.47% | -36.5% | -9.5% | -1.06% | -0.15% |
Earnings before Tax (EBT) 1 | - | -60.4 | -61.32 | -44.66 | -17.41 | -4.57 | -2.805 |
Net income 1 | -3.137 | -63.36 | -61.77 | -48.64 | -23.7 | -9.868 | -8.305 |
Net margin | - | -169.9% | -66.51% | -40.86% | -15.54% | -4.9% | -3.39% |
EPS 2 | -0.3500 | -4.440 | -2.290 | -1.570 | -0.7000 | -0.4325 | -0.2200 |
Free Cash Flow 1 | - | -12.13 | -36.47 | - | - | 4.524 | 14.91 |
FCF margin | - | -32.53% | -39.26% | - | - | 2.25% | 6.09% |
FCF Conversion (EBITDA) | - | - | - | - | - | 23.26% | 55.42% |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 24.95 | 27.42 | 29.04 | 30.46 | 31.41 | 28.12 | 33.13 | 35.95 | 38.61 | 44.86 | 42.59 | 47.15 | 52.15 | 59.53 | 52.72 |
EBITDA 1 | -9.049 | -8.219 | -7.584 | -6.927 | -1 | 0.6307 | 2 | 1.733 | 2.775 | 5.489 | 1.262 | 3.414 | 5.558 | 9.103 | 3.824 |
EBIT 1 | -12.59 | -13.66 | -13.11 | -15.64 | -6.818 | -10.37 | -2.853 | -4.896 | -4.569 | -2.172 | -3.752 | -1.588 | 0.3884 | 2.815 | -3.294 |
Operating Margin | -50.47% | -49.84% | -45.13% | -51.35% | -21.7% | -36.88% | -8.61% | -13.62% | -11.83% | -4.84% | -8.81% | -3.37% | 0.74% | 4.73% | -6.25% |
Earnings before Tax (EBT) 1 | -14.42 | -18 | -13.27 | -12.97 | -7.198 | -11.21 | -3.442 | -5.891 | -5.283 | -2.794 | -4.382 | -2.202 | -0.212 | 2.226 | -3.864 |
Net income 1 | -14.35 | -18.98 | -14.08 | -13.8 | -8.058 | -12.71 | -4.785 | -7.51 | -6.899 | -4.509 | -5.716 | -3.536 | -1.531 | 0.9138 | -5.15 |
Net margin | -57.54% | -69.24% | -48.47% | -45.29% | -25.65% | -45.21% | -14.44% | -20.89% | -17.87% | -10.05% | -13.42% | -7.5% | -2.94% | 1.54% | -9.77% |
EPS 2 | -0.5400 | -0.6300 | -0.4600 | -0.4500 | -0.2600 | -0.4000 | -0.1500 | -0.2300 | -0.2000 | -0.1200 | -0.1700 | -0.1325 | -0.0925 | -0.0400 | -0.1400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/7/22 | 5/13/22 | 8/11/22 | 11/10/22 | 3/22/23 | 5/12/23 | 8/9/23 | 11/8/23 | 3/11/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | 40.7 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -12.1 | -36.5 | - | - | 4.52 | 14.9 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | 3.38 | - | - | 0.3 | 0.3 |
Capex / Sales | - | - | 3.64% | - | - | 0.15% | 0.12% |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.18% | 482M | |
+4.71% | 32.47B | |
+16.51% | 7.45B | |
+23.49% | 3.89B | |
-15.80% | 3.17B | |
-27.19% | 1.28B | |
-33.58% | 1.09B | |
-33.74% | 902M | |
+1.56% | 893M | |
-23.93% | 857M |
- Stock Market
- Equities
- LFMD Stock
- Financials LifeMD, Inc.